The University of the Sciences research team has uncovered CAPER as a novel therapeutic target inside breast cancer cells. CAPER has been shown to be overexpressed in these cancer cells and seems to be helping the cancer thrive and survive. Targeted cancer therapy is becoming a leading approach to cancer treatment and Dr. Jasmin and […]
When it comes to administration of recombinant human growth hormone (r-hGh), short half-life, instability in gastrointestinal tract, and low circulation time requiring frequent parenteral administration can lead to patient noncompliance. Researchers are investigating several polymer nanoparticle and micro particle based long acting delivery systems. However, comprehension of structural stability and polymer grade is fundamental for […]
Unmet Need Syntheses of phenethylamines in a rapid and efficient manner. Dr. Adejare’s demonstrated technology can save time, reagents, and number of steps in syntheses of arylalkylamines. The pharmaceutically relevant chemical classes include: phenylethylamines, alpha-alkylphenylethylamines, tryptamines, and arylcyclohexylamines. Opportunity Many fine chemicals, pharmaceutical products, and / or their intermediates can be synthesized using this technology. […]
Human growth hormone (hGH), also known as somatotropin or somatropin, is a peptide hormone that stimulates growth and differentiation of target tissues. Exogenously administered hGH can be an effective treatment for growth disorders in both children and adults. It also is useful in treating catabolic disorders such as muscle wasting associated with acquired immunodeficiency syndrome […]
The Glucagon-Like Peptide 1 Receptor (GLP-1R), a member of Class B family of G-protein coupled receptors (GPCRs), is an effective target for the treatment of type-2 diabetes, and its incretin peptide and varied peptide mimetics are adopted drugs. Despite remarkable anti-diabetic effects, GLP-1R peptide-based agonists are limited by several disadvantages. Although considerable progress has been […]
TechTransCo, LLC d/b/a L2C Partners (“L2C Partners”) is not a registered broker-dealer or a registered investment adviser. You understand that the business plans of the companies posted on this website are furnished for your personal, noncommercial, informational purposes only, and that the inclusion of any company’s business plan (a “Company Plan”) on this website does not constitute an offer to sell, or a recommendation to buy, sell, or hold, any security of that company. To the extent that any of the information contained in any Company Plan may be deemed to be an offer to sell securities or investment advice, such information is impersonal and not directed towards any specific person. You agree and acknowledge that you are responsible for your own investment decisions with respect to any security of a company whose Company Plan is posted on this website.
L2C Partners has not reviewed any Company Plan posted on this website, and does not represent or warrant that any such Company Plan is accurate, reliable, correct or complete. THE COMPANY PLANS ARE PROVIDED "AS IS," “WHERE IS” AND “WITH ALL FAULTS,” AND L2C PARTNERS MAKES NO WARRANTY WITH RESPECT TO ANY COMPANY PLAN OF ANY KIND, EXPRESS, IMPLIED OR STATUTORY, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF ACCURACY, COMPLETENESS, TIMELINESS, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NONINFRINGEMENT, AND EXPRESSLY DISCLAIMS ALL SUCH WARRANTIES.
YOU AGREE AND ACKNOWLEDGE THAT NEITHER L2C PARTNERS NOR ITS AFFILIATES, MEMBERS, MANAGERS, OFFICERS, EMPLOYEES, BUSINESS PARTNERS, ADVISORS OR AGENTS (THE “L2C PARTIES”) SHALL HAVE ANY LIABILITY (JOINTLY OR SEVERALLY) TO YOU OR TO ANY OTHER PERSON FOR THE ACCURACY, RELIABILITY, CORRECTNESS OR COMPLETENESS OF ANY SUCH COMPANY PLAN, OR FOR ANY LOSSES, DAMAGES, EXPENSES, CLAIMS, OBLIGATIONS OR LIABILITIES, INCLUDING, WITHOUT LIMITATION, INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, EXEMPLARY OR PUNITIVE DAMAGES, INCLUDING LOST PROFITS (COLLECTIVELY, THE “EXCLUDED DAMAGES”), ARISING FROM OR RELATED TO YOUR OR ANY OTHER PERSON’S USE OF OR RELIANCE ON THE CONTENT OF ANY COMPANY PLAN, WHETHER OR NOT CHARACTERIZED IN NEGLIGENCE, TORT, CONTRACT, OR OTHER THEORY OF LIABILITY, EVEN IF ANY OF THE L2C PARTIES HAVE BEEN ADVISED OF THE POSSIBILITY OF OR COULD HAVE FORESEEN ANY OF THE EXCLUDED DAMAGES. IF ANY PORTION OF THIS DISCLAIMER IS HELD TO BE UNENFORCEABLE, THEN THE L2C PARTIES' LIABILITY WILL BE LIMITED TO THE FULLEST POSSIBLE EXTENT PERMITTED BY APPLICABLE LAW.